https://www.selleckchem.com/products/ag-270.html
MammaPrint (MP) has been applied in South Africa (SA) for decision-making in early-stage hormone receptor-positive breast cancer since 2006. The cost-impact of MP in SA has not been assessed. To assess different MP testing strategies for cost-minimization in early-stage breast carcinoma using a funder perspective. Clinico-pathologic information was extracted from a prospectively collected database. Clinical risk stratification was done using Adjuvant Online! (AOL) and the Predict V2.1 algorithm (www.predict.nhs.uk). An unselected MP test
Gefällt mir
Kommentar
Teilen
